Navigation Links
VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
Date:1/16/2008

ficacy of VIA-2291;

-- the outcome of any legal proceedings;

-- our ability to obtain necessary FDA approvals;

-- our ability to successfully commercialize VIA-2291;

-- our ability to obtain and protect our intellectual property related to

our product candidates;

-- our potential for future growth and the development of our product

pipeline;

-- our ability to form and maintain collaborative relationships to

develop and commercialize our product candidates;

-- general economic and business conditions; and

-- the other risks described under the heading "Risk Factors" in our

Quarterly Reports on Form 10-Q for the quarters ended June 30, 2007

and September 30, 2007 on file with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
4. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
5. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
6. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
7. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
8. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
11. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):U. of I. business instructional facility achieves top 'green' standard 2U. of I. business instructional facility achieves top 'green' standard 3Rodent smoke screen 2Plate-eating good: Université de Montréal professor designs edible tableware 2DATATRAK Announces the Award of New Studies from European Pharmaceutical Clients 59623 1DATATRAK Announces the Award of New Studies from European Pharmaceutical Clients 59623 2DATATRAK Announces the Award of New Studies from European Pharmaceutical Clients 59623 3The Medco Foundation Joins With the Entertainment Industry Foundation to Give Health a Hand to Communities in Need 5526 1The Medco Foundation Joins With the Entertainment Industry Foundation to Give Health a Hand to Communities in Need 5526 2The Medco Foundation Joins With the Entertainment Industry Foundation to Give Health a Hand to Communities in Need 5526 3Elseviers BrainNavigator Research Tool to Launch new Features at Neuroscience 2009 Show 14505 1Elseviers BrainNavigator Research Tool to Launch new Features at Neuroscience 2009 Show 14505 2Elseviers BrainNavigator Research Tool to Launch new Features at Neuroscience 2009 Show 14505 3Elseviers BrainNavigator Research Tool to Launch new Features at Neuroscience 2009 Show 14505 4Elseviers BrainNavigator Research Tool to Launch new Features at Neuroscience 2009 Show 14505 5